| Item Type | Name |
|
Concept
|
Hyperlipidemias
|
|
Concept
|
Hyperlipidemia, Familial Combined
|
|
Academic Article
|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
|
|
Academic Article
|
Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women.
|
|
Academic Article
|
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Risk of cardiovascular disease and sudden death in schizophrenia.
|
|
Academic Article
|
Possible differences between fibrates in pharmacokinetic interactions with statins.
|
|
Academic Article
|
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
|
|
Academic Article
|
Comparative effects of lipid-lowering therapies.
|
|
Academic Article
|
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
|
|
Academic Article
|
Lipid-lowering effects of statins: a comparative review.
|
|
Academic Article
|
Differences between clinical trial efficacy and real-world effectiveness.
|
|
Academic Article
|
Biologic therapies for dyslipidemia.
|
|
Academic Article
|
Combination therapy in the management of complex dyslipidemias.
|
|
Academic Article
|
Management of dyslipidemia in patients with complicated metabolic syndrome.
|
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
|
Academic Article
|
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia.
|
|
Academic Article
|
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
|
|
Academic Article
|
Risk for myopathy with statin therapy in high-risk patients.
|
|
Academic Article
|
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
|
|
Academic Article
|
Newer pharmaceutical agents to treat lipid disorders.
|
|
Academic Article
|
Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.
|
|
Academic Article
|
Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data.
|
|
Academic Article
|
Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids.
|
|
Academic Article
|
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
|
|
Academic Article
|
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
|
|
Academic Article
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
|
Academic Article
|
Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?
|
|
Academic Article
|
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Marine oil capsule therapy for the treatment of hyperlipidemia.
|
|
Academic Article
|
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.
|
|
Academic Article
|
ETC-1002: a future option for lipid disorders?
|
|
Academic Article
|
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
|